title: Proximal femoral bone loss and increased rate of fracture with a proximally hydroxyapatite-coated femoral component.
abstract: We performed a retrospective analysis of the clinical and radiological outcomes of total hip replacement using an uncemented femoral component proximally coated with hydroxyapatite. Of 136 patients, 118 who had undergone 124 primary total hip replacements were available for study. Their mean age was 66.5 years (19 to 90) and the mean follow-up was 5.6 years (4.25 to 7.25). At the final follow-up the mean Harris hip score was 92 (47.7 to 100). Periprosthetic femoral fractures, which occurred in seven patients (5.6%), were treated by osteosynthesis in six and conservatively in one. We had to revise five femoral components, one because of aseptic loosening, one because of septic loosening and three because of periprosthetic fracture. At the final follow-up there were definite signs of aseptic loosening in two patients. Radiologically, proximal femoral bone loss in Gruen zones I and VI was evident in 96.8% of hips, while bone hypertrophy in zones III and V was seen in 64.7%. In 24 hips (20.2%) the mean subsidence of the stem was 3.7 mm which occurred within the first 12 postoperative weeks. This indicated poor initial stability, which might have been aggravated by early weight-bearing. The high rate of failure in our study suggests that proximal femoral bone loss affects the long-term survival of the replacement.
authors.affiliation: Department of Orthopaedics, Karl-Franzens University, Graz, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Radl
authors.forename: C
authors.initials: C
authors.lastname: Aigner
authors.forename: M
authors.initials: M
authors.lastname: Hungerford
authors.forename: A
authors.initials: A
authors.lastname: Pascher
authors.forename: R
authors.initials: R
authors.lastname: Windhager
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D017886:Durapatite / Q000627:therapeutic use*; D004434:Early Ambulation / Q000009:adverse effects; D019544:Equipment Failure Analysis; D005260:Female; D005264:Femoral Fractures / Q000000981:diagnostic imaging* / Q000209:etiology*; D006801:Humans; D015576:Hyperostosis / Q000000981:diagnostic imaging* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D016348:Osseointegration; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D011475:Prosthesis Failure; D011859:Radiography; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D016474:Weight-Bearing
chemical_list: D001672:Biocompatible Materials; D020099:Coated Materials, Biocompatible; D017886:Durapatite